Vera Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Vera Therapeutics, Inc. (VERA) reported Earnings Per Share, Basic and Diluted of -$0.71 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-16
- Vera Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.71.
- Vera Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.79.
- Vera Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.36.
- Vera Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.33.
- Vera Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.43.
- Vera Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$166.93.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.71 10-Q · filed 2022-05-16 | -$1.49 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.86 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.33 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2021-12-31 | -$0.79 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$1.15 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$1.58 derived: net income ÷ weighted average shares · filed 2023-03-28 | -$2.43 10-K · filed 2022-03-28 |
| 2021-09-30 | -$0.36 10-Q · filed 2021-11-10 | -$0.70 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$1.46 10-Q · filed 2021-11-10 | -$7.23 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2021-06-30 | -$0.33 10-Q · filed 2021-08-16 | -$1.49 10-Q · filed 2021-08-16 | -$13.67 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$19.26 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2021-03-31 | -$12.23 10-Q · filed 2022-05-16 | -$136.59 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$152.67 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$165.20 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2020-12-31 | -$137.68 derived: net income ÷ weighted average shares · filed 2022-03-28 | -$148.52 derived: net income ÷ weighted average shares · filed 2022-03-28 | -$158.83 derived: net income ÷ weighted average shares · filed 2022-03-28 | -$166.93 10-K · filed 2022-03-28 |
| 2020-09-30 | -$13.68 10-Q · filed 2021-11-10 | -$24.79 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$32.64 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$11.10 10-Q · filed 2021-08-16 | -$18.92 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$7.79 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |